DOI: 10.26155/vet.zoo.bio.202011004
UDC 636.1
Authors
Rozhdestvenskaya T. N.,
Doctor of Veterinary Sciences, Director for Science,
Scientific-Production Enterprise “AVIVAC”,
Saint-Petersburg, Russian Federation
Head of the Laboratory of Bird Diseases. Federal Scientific Center –
All-Russian Scientific Research Institute of Experimental
Veterinary Medicine named after K. I. Scriabin and
Ya. R. Kovalenko of the Russian Academy of Sciences,
Moscow, Russian Federation
Pankratov S. V.
Candidate of Veterinary Sciences, Deputy Director for Quality,
Scientific-Production Enterprise “AVIVAC”,
Saint-Petersburg, Russian Federation
Sapegina Е. V.
Serologist, Deputy Director of Diagnostic Center,
Scientific-Production Enterprise “AVIVAC”,
Saint-Petersburg, Russian Federation
Tomina Е.V.
Head of Quality Control Department, Scientific-
Production Enterprise “AVIVAC”
Saint-Petersburg, Russian Federation
Abstract
This article presents the results of testing vaccines against avian hemophilia based on inactivated
antigens of Avibacterium paragallinarum serotypes “A”, “B” and “C” using GOA adjuvant
and Montanide ISA 71 R VG oil adjuvant (manufactured by SEPPIC, France).
The relevance of this work is dictated by the need to research the most immunogenic and less
reactogenic adjuvants for inactivated vaccines against avian hemophilia. Successful prevention of
infectious diseases should be based on an integrated approach and provide not only for the implementation
of veterinary and sanitary measures, full compliance with poultry growing technologies
and the use of effective therapeutic drugs, but also for the use of modern and safe means of specific
prophylaxis (vaccine prophylaxis).
hemophiliа made with the use of GOA adjuvant and Montanide ISA-71 R VG adjuvant completely
correspond to the main quality criteria of preparation of this class – having no reactogenicity and have
sufficient protective properties to protect birds from infection with field pathogens of hemophilia.
Keywords
Avibacterium paragallinarum, avian hemophilia, bacterial diseases, mixed infection, adjuvants, inactivated vaccines, vaccine prophylaxis, reactogenicity, protective properties.